The role of staphylococcus aureus virulence factors in skin infection and their potential as vaccine antigens

Pathogens

Volumn 5, Issue 1, 2016, Pages

  Lacey, Keenan A ^a   Geoghegan, Joan A ^a   McLoughlin, Rachel M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cell wall anchored proteins; Skin infection; Staphylococcus aureus; Vaccine development; Virulence factors

Indexed keywords

ADAM10 ENDOPEPTIDASE; BACTERIAL ANTIGEN; CELL MEMBRANE PROTEIN; CLUMPING FACTOR A; CLUMPING FACTOR B; FIBRONECTIN BINDING PROTEIN; IRON REGULATED SURFACE PROTEIN; PEPTIDOGLYCAN; PROTEIN A; SASX PROTEIN; STAPHYLOCOCCUS VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTHRITIS; BLOODSTREAM INFECTION; CANDIDA ALBICANS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 85026262422     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens5010022     Document Type: Review

References (108)

1. Hersh, A.L.; Chambers, H.F.; Maselli, J.H.; Gonzales, R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch. Internal Med. 2008, 168, 1585-1591. [CrossRef] [PubMed]
2. David, M.Z.; Daum, R.S. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010, 23, 616-687. [CrossRef] [PubMed]
3. Otto, M. Basis of virulence in community-associated methicillin-resistant staphylococcus aureus. Annu. Rev. Microbiol. 2010, 64, 143-162. [CrossRef] [PubMed]
4. Proctor, R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 2012, 54, 1179-1186. [CrossRef] [PubMed]
5. Fowler, V.G., Jr.; Proctor, R.A. Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 2014, 20 (Suppl. 5), 66-75. [CrossRef] [PubMed]
6. Laupland, K.B.; Ross, T.; Gregson, D.B. Staphylococcus aureus bloodstream infections: Risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J. Infect. Dis. 2008, 198, 336-343. [CrossRef] [PubMed]
7. Spellberg, B.; Ibrahim, A.S.; Yeaman, M.R.; Lin, L.; Fu, Y.; Avanesian, V.; Bayer, A.S.; Filler, S.G.; Lipke, P.; Otoo, H.; et al. The antifungal vaccine derived from the recombinant n terminus of als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immunity 2008, 76, 4574-4580. [CrossRef] [PubMed]
8. Daum, R.S.; Spellberg, B. Progress toward a Staphylococcus aureus vaccine. Clin. Infect. Dis. 2012, 54, 560-567. [CrossRef] [PubMed]
9. Misstear, K.; McNeela, E.A.; Murphy, A.G.; Geoghegan, J.A.; O’Keeffe, K.M.; Fox, J.; Chan, K.; Heuking, S.; Collin, N.; Foster, T.J.; et al. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. J. Infect. Dis. 2014, 209, 1479-1484. [CrossRef] [PubMed]
10. Wiese, L.; Mejer, N.; Schonheyder, H.C.; Westh, H.; Jensen, A.G.; Larsen, A.R.; Skov, R.; Benfield, T. A nationwide study of comorbidity and risk of reinfection after Staphylococcus aureus bacteraemia. J. Infect. 2013, 67, 199-205. [CrossRef] [PubMed]
11. Holland, S.M.; DeLeo, F.R.; Elloumi, H.Z.; Hsu, A.P.; Uzel, G.; Brodsky, N.; Freeman, A.F.; Demidowich, A.; Davis, J.; Turner, M.L.; et al. Stat3 mutations in the hyper-ige syndrome. N. Engl. J. Med. 2007, 357, 1608-1619. [CrossRef] [PubMed]
12. Litjens, N.H.; Huisman, M.; van den Dorpel, M.; Betjes, M.G. Impaired immune responses and antigen-specific memory cd4+ T cells in hemodialysis patients. J. Am. Soc. Nephrol. 2008, 19, 1483-1490. [CrossRef] [PubMed]
13. Milner, J.D.; Brenchley, J.M.; Laurence, A.; Freeman, A.F.; Hill, B.J.; Elias, K.M.; Kanno, Y.; Spalding, C.; Elloumi, H.Z.; Paulson, M.L.; et al. Impaired t(h)17 cell differentiation in subjects with autosomal dominant hyper-ige syndrome. Nature 2008, 452, 773-776. [CrossRef] [PubMed]
14. Ishigame, H.; Kakuta, S.; Nagai, T.; Kadoki, M.; Nambu, A.; Komiyama, Y.; Fujikado, N.; Tanahashi, Y.; Akitsu, A.; Kotaki, H.; et al. Differential roles of interleukin-17a and -17f in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30, 108-119. [CrossRef] [PubMed]
15. Brown, A.F.; Murphy, A.G.; Lalor, S.J.; Leech, J.M.; O’Keeffe, K.M.; Mac Aogain, M.; O’Halloran, D.P.; Lacey, K.A.; Tavakol, M.; Hearnden, C.H.; et al. Memory th1 cells are protective in invasive Staphylococcus aureus infection. PLoS Pathog. 2015, 11, e1005226. [CrossRef] [PubMed]
16. Pier, G.B. Will there ever be a universal Staphylococcus aureus vaccine? Hum. Vaccin. Immunother. 2013, 9, 1865-1876. [CrossRef] [PubMed]
17. Miller, L.S.; Cho, J.S. Immunity against Staphylococcus aureus cutaneous infections. Nat. Rev. Immunol. 2011, 11, 505-518. [CrossRef] [PubMed]
18. Krishna, S.; Miller, L.S. Host-pathogen interactions between the skin and Staphylococcus aureus. Curr. Opin. Microbiol. 2012, 15, 28-35. [CrossRef] [PubMed]
19. Nestle, F.O.; Di Meglio, P.; Qin, J.Z.; Nickoloff, B.J. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009, 9, 679-691. [CrossRef] [PubMed]
20. Moran, G.J.; Abrahamian, F.M.; LoVecchio, F.; Talan, D.A. Acute bacterial skin infections: Developments since the 2005 infectious diseases society of america (idsa) guidelines. J. Emerg. Med. 2013, 44, e397-e412. [CrossRef] [PubMed]
21. Ki, V.; Rotstein, C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can. J. Infect. Dis. Med. Microbiol. 2008, 19, 173-184. [PubMed]
22. Moran, G.J.; Krishnadasan, A.; Gorwitz, R.J.; Fosheim, G.E.; McDougal, L.K.; Carey, R.B.; Talan, D.A. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 2006, 355, 666-674. [CrossRef] [PubMed]
23. Bae, I.G.; Tonthat, G.T.; Stryjewski, M.E.; Rude, T.H.; Reilly, L.F.; Barriere, S.L.; Genter, F.C.; Corey, G.R.; Fowler, V.G., Jr. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: Results of a multinational trial. J. Clin. Microbiol. 2009, 47, 3952-3957. [PubMed]
24. Kobayashi, S.D.; Malachowa, N.; DeLeo, F.R. Pathogenesis of Staphylococcus aureus abscesses. Am. J. Pathol. 2015, 185, 1518-1527. [CrossRef] [PubMed]
25. Men, S.; Akhan, O.; Koroglu, M. Percutaneous drainage of abdominal abcess. Eur. J. Radiol. 2002, 43, 204-218. [CrossRef]
26. Kupper, T.S.; Fuhlbrigge, R.C. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat. Rev. Immunol. 2004, 4, 211-222. [CrossRef] [PubMed]
27. Miller, L.S. Toll-like receptors in skin. Adv. Dermatol. 2008, 24, 71-87. [CrossRef] [PubMed]
28. Von Bernuth, H.; Picard, C.; Jin, Z.; Pankla, R.; Xiao, H.; Ku, C.L.; Chrabieh, M.; Mustapha, I.B.; Ghandil, P.; Camcioglu, Y.; et al. Pyogenic bacterial infections in humans with myd88 deficiency. Science 2008, 321, 691-696. [CrossRef] [PubMed]
29. Picard, C.; Puel, A.; Bonnet, M.; Ku, C.L.; Bustamante, J.; Yang, K.; Soudais, C.; Dupuis, S.; Feinberg, J.; Fieschi, C.; et al. Pyogenic bacterial infections in humans with irak-4 deficiency. Science 2003, 299, 2076-2079. [CrossRef] [PubMed]
30. Miller, L.S.; O’Connell, R.M.; Gutierrez, M.A.; Pietras, E.M.; Shahangian, A.; Gross, C.E.; Thirumala, A.; Cheung, A.L.; Cheng, G.; Modlin, R.L. Myd88 mediates neutrophil recruitment initiated by il-1r but not tlr2 activation in immunity against Staphylococcus aureus. Immunity 2006, 24, 79-91. [CrossRef] [PubMed]
31. Ku, C.L.; von Bernuth, H.; Picard, C.; Zhang, S.Y.; Chang, H.H.; Yang, K.; Chrabieh, M.; Issekutz, A.C.; Cunningham, C.K.; Gallin, J.; et al. Selective predisposition to bacterial infections in irak-4-deficient children: Irak-4-dependent tlrs are otherwise redundant in protective immunity. J. Exp. Med. 2007, 204, 2407-2422. [CrossRef] [PubMed]
32. Sutton, C.E.; Lalor, S.J.; Sweeney, C.M.; Brereton, C.F.; Lavelle, E.C.; Mills, K.H. Interleukin-1 and il-23 induce innate il-17 production from gammadelta T cells, amplifying th17 responses and autoimmunity. Immunity 2009, 31, 331-341. [CrossRef] [PubMed]
33. Cua, D.J.; Tato, C.M. Innate il-17-producing cells: The sentinels of the immune system. Nat. Rev. Immunol. 2010, 10, 479-489. [CrossRef] [PubMed]
34. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V.K. Il-17 and th17 cells. Nat. Rev. Immunol. 2009, 27, 485-517. [CrossRef] [PubMed]
35. Cho, J.S.; Pietras, E.M.; Garcia, N.C.; Ramos, R.I.; Farzam, D.M.; Monroe, H.R.; Magorien, J.E.; Blauvelt, A.; Kolls, J.K.; Cheung, A.L.; et al. Il-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Investig. 2010, 120, 1762-1773. [CrossRef] [PubMed]
36. Liang, S.C.; Tan, X.Y.; Luxenberg, D.P.; Karim, R.; Dunussi-Joannopoulos, K.; Collins, M.; Fouser, L.A. Interleukin (il)-22 and il-17 are coexpressed by th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203, 2271-2279. [CrossRef] [PubMed]
37. Yeaman, M.R.; Filler, S.G.; Chaili, S.; Barr, K.; Wang, H.; Kupferwasser, D.; Hennessey, J.P; Fu, Y.; Schmidt, C.S.; Edwards, J.E. Mechanisms of ndv-3 vaccine efficacy in mrsa skin versus invasive infection. Proc. Natl. Acad. Sci. USA 2014, 111, E5555-E5563. [CrossRef] [PubMed]
38. Chan, L.C.; Chaili, S.; Filler, S.G.; Barr, K.; Wang, H.; Kupferwasser, D.; Edwards, J.E.; Xiong, Y.Q.; Ibrahim, A.S.; Miller, L.S.; et al. Non-redundant roles of il-17a and il-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus. Infect. Immunity 2015. [CrossRef] [PubMed]
39. Spaan, A.N.; Henry, T.; van Rooijen, W.J.; Perret, M.; Badiou, C.; Aerts, P.C.; Kemmink, J.; de Haas, C.J.; van Kessel, K.P.; Vandenesch, F.; et al. The staphylococcal toxin panton-valentine leukocidin targets human c5a receptors. Cell Host Microbe 2013, 13, 584-594. [CrossRef] [PubMed]
40. Loffler, B.; Hussain, M.; Grundmeier, M.; Bruck, M.; Holzinger, D.; Varga, G.; Roth, J.; Kahl, B.C.; Proctor, R.A.; Peters, G. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010, 6, e1000715. [CrossRef] [PubMed]
41. Malachowa, N.; Kobayashi, S.D.; Braughton, K.R.; Whitney, A.R.; Parnell, M.J.; Gardner, D.J.; Deleo, F.R. Staphylococcus aureus leukotoxin gh promotes inflammation. J. Infect. Dis. 2012, 206, 1185-1193. [CrossRef] [PubMed]
42. Morinaga, N.; Kaihou, Y.; Noda, M. Purification, cloning and characterization of variant luke-lukd with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol. Immunol. 2003, 47, 81-90. [CrossRef] [PubMed]
43. Kobayashi, S.D.; Malachowa, N.; Whitney, A.R.; Braughton, K.R.; Gardner, D.J.; Long, D.; Bubeck Wardenburg, J.; Schneewind, O.; Otto, M.; Deleo, F.R. Comparative analysis of usa300 virulence determinants in a rabbit model of skin and soft tissue infection. J. Infect. Dis. 2011, 204, 937-941. [CrossRef] [PubMed]
44. Lipinska, U.; Hermans, K.; Meulemans, L.; Dumitrescu, O.; Badiou, C.; Duchateau, L.; Haesebrouck, F.; Etienne, J.; Lina, G. Panton-valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: A rabbit model. PLoS ONE 2011, 6, e22864. [CrossRef] [PubMed]
45. Malachowa, N.; Kobayashi, S.D.; Sturdevant, D.E.; Scott, D.P.; DeLeo, F.R. Insights into the Staphylococcus aureus-host interface: Global changes in host and pathogen gene expression in a rabbit skin infection model. PLoS ONE 2015, 10, e0117713. [CrossRef] [PubMed]
46. Yoong, P.; Torres, V.J. Counter inhibition between leukotoxins attenuates Staphylococcus aureus virulence. Nat. Commun. 2015, 6, 8125. [CrossRef] [PubMed]
47. Ezepchuk, Y.V.; Leung, D.Y.; Middleton, M.H.; Bina, P.; Reiser, R.; Norris, D.A. Staphylococcal toxins and protein a differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. J. Investig. Dermatol. 1996, 107, 603-609. [CrossRef] [PubMed]
48. Hocke, A.C.; Temmesfeld-Wollbrueck, B.; Schmeck, B.; Berger, K.; Frisch, E.M.; Witzenrath, M.; Brell, B.; Suttorp, N.; Hippenstiel, S. Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: Inhibition of endothelial gap formation by adrenomedullin. Histochem. Cell Biol. 2006, 126, 305-316. [CrossRef] [PubMed]
49. Thelestam, M.; Mollby, R.; Wadstrom, T. Effects of staphylococcal alpha-, beta-, delta-, and gammahemolysins on human diploid fibroblasts and hela cells: Evaluation of a new quantitative as say for measuring cell damage. Infect. Immunity 1973, 8, 938-946.
50. Walev, I.; Martin, E.; Jonas, D.; Mohamadzadeh, M.; Muller-Klieser, W.; Kunz, L.; Bhakdi, S. Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect. Immunity 1993, 61, 4972-4979.
51. Wilke, G.A.; Bubeck Wardenburg, J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. USA 2010, 107, 13473-13478. [CrossRef] [PubMed]
52. Ebsen, H.; Schröder, A.; Kabelitz, D.; Janssen, O. Differential surface expression of adam10 and adam17 on human T lymphocytes and tumor cells. PLoS ONE 2013, 8, e76853. [CrossRef] [PubMed]
53. Kennedy, A.D.; Bubeck Wardenburg, J.; Gardner, D.J.; Long, D.; Whitney, A.R.; Braughton, K.R.; Schneewind, O.; DeLeo, F.R. Targeting of alpha-hemolysin by active or passive immunization decreases severity of usa300 skin infection in a mouse model. J. Infect. Dis. 2010, 202, 1050-1058. [CrossRef] [PubMed]
54. Chen, Y.; Yeh, A.J.; Cheung, G.Y.; Villaruz, A.E.; Tan, V.Y.; Joo, H.S.; Chatterjee, S.S.; Yu, Y.; Otto, M. Basis of virulence in a panton-valentine leukocidin-negative community-associated methicillin-resistant Staphylococcus aureus strain. J. Infect. Dis. 2015, 211, 472-480. [CrossRef] [PubMed]
55. Chua, K.Y.; Monk, I.R.; Lin, Y.H.; Seemann, T.; Tuck, K.L.; Porter, J.L.; Stepnell, J.; Coombs, G.W.; Davies, J.K.; Stinear, T.P.; et al. Hyperexpression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol. 2014, 14, 31. [CrossRef] [PubMed]
56. Tkaczyk, C.; Hua, L.; Varkey, R.; Shi, Y.; Dettinger, L.; Woods, R.; Barnes, A.; MacGill, R.S.; Wilson, S.; Chowdhury, P.; et al. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin. Vaccine Immunol. 2012, 19, 377-385. [CrossRef] [PubMed]
57. Otto, M. Phenol-soluble modulins. Int. J. Med. Microbiol. 2014, 304, 164-169. [CrossRef] [PubMed]
58. Wang, R.; Braughton, K.R.; Kretschmer, D.; Bach, T.-H.L.; Queck, S.Y.; Li, M.; Kennedy, A.D.; Dorward, D.W.; Klebanoff, S.J.; Peschel, A.; et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated mrsa. Nat. Med. 2007, 13, 1510-1514. [CrossRef] [PubMed]
59. Cheung, G.Y.; Kretschmer, D.; Queck, S.Y.; Joo, H.S.; Wang, R.; Duong, A.C.; Nguyen, T.H.; Bach, T.H.; Porter, A.R.; DeLeo, F.R.; et al. Insight into structure-function relationship in phenol-soluble modulins using an alanine screen of the phenol-soluble modulin (psm) alpha3 peptide. FASEB J. 2014, 28, 153-161. [CrossRef] [PubMed]
60. Surewaard, B.G.; de Haas, C.J.; Vervoort, F.; Rigby, K.M.; DeLeo, F.R.; Otto, M.; van Strijp, J.A.; Nijland, R. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cell. Microbiol. 2013, 15, 1427-1437. [CrossRef] [PubMed]
61. Geiger, T.; Francois, P.; Liebeke, M.; Fraunholz, M.; Goerke, C.; Krismer, B.; Schrenzel, J.; Lalk, M.; Wolz, C. The stringent response of Staphylococcus aureus and its impact on survival after phagocytosis through the induction of intracellular psms expression. PLoS Pathog. 2012, 8, e1003016. [CrossRef] [PubMed]
62. Foster, T.J.; Geoghegan, J.A.; Ganesh, V.K.; Hook, M. Adhesion, invasion and evasion: The many functions of the surface proteins of Staphylococcus aureus. Nat. Rev. Microbiol. 2014, 12, 49-62. [CrossRef] [PubMed]
63. Hendrickx, A.P.; Budzik, J.M.; Oh, S.Y.; Schneewind, O. Architects at the bacterial surface—Sortases and the assembly of pili with isopeptide bonds. Nat. Rev. Microbiol. 2011, 9, 166-176. [CrossRef] [PubMed]
64. Mazmanian, S.K.; Liu, G.; Jensen, E.R.; Lenoy, E.; Schneewind, O. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc. Natl. Acad. Sci. USA 2000, 97, 5510-5515. [CrossRef] [PubMed]
65. Cheng, A.G.; Kim, H.K.; Burts, M.L.; Krausz, T.; Schneewind, O.; Missiakas, D.M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 2009, 23, 3393-3404. [CrossRef] [PubMed]
66. Kwiecinski, J.; Jin, T.; Josefsson, E. Surface proteins of Staphylococcus aureus play an important role in experimental skin infection. APMIS 2014, 122, 1240-1245. [CrossRef] [PubMed]
67. McDevitt, D.; Nanavaty, T.; House-Pompeo, K.; Bell, E.; Turner, N.; McIntire, L.; Foster, T.; Hook, M. Characterization of the interaction between the Staphylococcus aureus clumping factor (clfa) and fibrinogen. Eur. J. Biochem. 1997, 247, 416-424. [CrossRef] [PubMed]
68. Josefsson, E.; Hartford, O.; O’Brien, L.; Patti, J.M.; Foster, T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor a, a novel virulence determinant. J. Infect. Dis. 2001, 184, 1572-1580. [CrossRef] [PubMed]
69. McAdow, M.; Kim, H.K.; Dedent, A.C.; Hendrickx, A.P.; Schneewind, O.; Missiakas, D.M. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 2011, 7, e1002307. [CrossRef] [PubMed]
70. Moreillon, P.; Entenza, J.M.; Francioli, P.; McDevitt, D.; Foster, T.J.; Francois, P.; Vaudaux, P. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immunity 1995, 63, 4738-4743.
71. Higgins, J.; Loughman, A.; van Kessel, K.P.; van Strijp, J.A.; Foster, T.J. Clumping factor a of Staphylococcus aureus inhibits phagocytosis by human polymorphonuclear leucocytes. FEMS Microbiol. Lett. 2006, 258, 290-296. [CrossRef] [PubMed]
72. Flick, M.J.; Du, X.; Prasad, J.M.; Raghu, H.; Palumbo, J.S.; Smeds, E.; Hook, M.; Degen, J.L. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor clfa improves host survival in septicemia. Blood 2013, 121, 1783-1794. [CrossRef] [PubMed]
73. Kolata, J.B.; Kuhbandner, I.; Link, C.; Normann, N.; Vu, C.H.; Steil, L.; Weidenmaier, C.; Broker, B.M. The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus aureus in humans. J. Infect. Dis. 2015, 212, 830-838. [CrossRef] [PubMed]
74. Mulcahy, M.E.; Geoghegan, J.A.; Monk, I.R.; O’Keeffe, K.M.; Walsh, E.J.; Foster, T.J.; McLoughlin, R.M. Nasal colonisation by Staphylococcus aureus depends upon clumping factor b binding to the squamous epithelial cell envelope protein loricrin. PLoS Pathog. 2012, 8, e1003092. [CrossRef] [PubMed]
75. Schaffer, A.C.; Solinga, R.M.; Cocchiaro, J.; Portoles, M.; Kiser, K.B.; Risley, A.; Randall, S.M.; Valtulina, V.; Speziale, P.; Walsh, E.; et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immunity 2006, 74, 2145-2153. [CrossRef] [PubMed]
76. Wertheim, H.F.; Walsh, E.; Choudhurry, R.; Melles, D.C.; Boelens, H.A.; Miajlovic, H.; Verbrugh, H.A.; Foster, T.; van Belkum, A. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med. 2008, 5, e17. [CrossRef] [PubMed]
77. Walsh, E.J.; Miajlovic, H.; Gorkun, O.V.; Foster, T.J. Identification of the Staphylococcus aureus mscramm clumping factor B (clfb) binding site in the alphac-domain of human fibrinogen. Microbiology 2008, 154, 550-558. [CrossRef] [PubMed]
78. Walsh, E.J.; O’Brien, L.M.; Liang, X.; Hook, M.; Foster, T.J. Clumping factor B, a fibrinogen-binding mscramm (microbial surface components recognizing adhesive matrix molecules) adhesin of Staphylococcus aureus, also binds to the tail region of type I cytokeratin 10. J. Biol. Chem. 2004, 279, 50691-50699. [CrossRef] [PubMed]
79. Steven, A.C.; Steinert, P.M. Protein composition of cornified cell envelopes of epidermal keratinocytes. J. Cell Sci. 1994, 107, 693-700. [PubMed]
80. Palmqvist, N.; Foster, T.; Fitzgerald, J.R.; Josefsson, E.; Tarkowski, A. Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation. J. Infect. Dis. 2005, 191, 791-798. [CrossRef] [PubMed]
81. Peacock, S.J.; Foster, T.J.; Cameron, B.J.; Berendt, A.R. Bacterial fibronectin-binding proteins and endothelial cell surface fibronectin mediate adherence of Staphylococcus aureus to resting human endothelial cells. Microbiology 1999, 145(Pt 12), 3477-3486. [CrossRef] [PubMed]
82. Sinha, B.; Francois, P.P.; Nusse, O.; Foti, M.; Hartford, O.M.; Vaudaux, P.; Foster, T.J.; Lew, D.P.; Herrmann, M.; Krause, K.H. Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell. Microbiol. 1999, 1, 101-117. [CrossRef] [PubMed]
83. Massey, R.C.; Kantzanou, M.N.; Fowler, T.; Day, N.P.; Schofield, K.; Wann, E.R.; Berendt, A.R.; Hook, M.; Peacock, S.J. Fibronectin-binding protein a of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell. Microbiol. 2001, 3, 839-851. [CrossRef] [PubMed]
84. Edwards, A.M.; Potts, J.R.; Josefsson, E.; Massey, R.C. Staphylococcus aureus host cell invasion and virulence in sepsis is facilitated by the multiple repeats within fnbpa. PLoS Pathog. 2010, 6, e1000964. [CrossRef] [PubMed]
85. Shinji, H.; Yosizawa, Y.; Tajima, A.; Iwase, T.; Sugimoto, S.; Seki, K.; Mizunoe, Y. Role of fibronectin-binding proteins a and B in in vitro cellular infections and in vivo septic infections by Staphylococcus aureus. Infect. Immunity 2011, 79, 2215-2223. [CrossRef] [PubMed]
86. Edwards, A.M.; Potter, U.; Meenan, N.A.; Potts, J.R.; Massey, R.C. Staphylococcus aureus keratinocyte invasion is dependent upon multiple high-affinity fibronectin-binding repeats within fnbpa. PLoS ONE 2011, 6, e18899. [CrossRef] [PubMed]
87. Li, M.; Du, X.; Villaruz, A.E.; Diep, B.A.; Wang, D.; Song, Y.; Tian, Y.; Hu, J.; Yu, F.; Lu, Y.; et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat. Med. 2012, 18, 816-819. [CrossRef] [PubMed]
88. Liu, Q.; Du, X.; Hong, X.; Li, T.; Zheng, B.; He, L.; Wang, Y.; Otto, M.; Li, M. Targeting surface protein sasx by active and passive vaccination to reduce Staphylococcus aureus colonization and infection. Infection Immunity 2015, 83, 2168-2174. [CrossRef] [PubMed]
89. Foster, T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3, 948-958. [CrossRef] [PubMed]
90. Lindmark, R.; Thoren-Tolling, K.; Sjoquist, J. Binding of immunoglobulins to protein a and immunoglobulin levels in mammalian sera. J. Immunol. Methods 1983, 62, 1-13. [CrossRef]
91. Goodyear, C.S.; Silverman, G.J. Death by a B cell superantigen: In vivo vh-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J. Exp. Med. 2003, 197, 1125-1139. [CrossRef] [PubMed]
92. Gomez, M.I.; Lee, A.; Reddy, B.; Muir, A.; Soong, G.; Pitt, A.; Cheung, A.; Prince, A. Staphylococcus aureus protein a induces airway epithelial inflammatory responses by activating tnfr1. Nat. Med. 2004, 10, 842-848. [CrossRef] [PubMed]
93. Kim, H.K.; Kim, H.Y.; Schneewind, O.; Missiakas, D. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 2011, 25, 3605-3612. [CrossRef] [PubMed]
94. Classen, A.; Kalali, B.N.; Schnopp, C.; Andres, C.; Aguilar-Pimentel, J.A.; Ring, J.; Ollert, M.; Mempel, M. Tnf receptor I on human keratinocytes is a binding partner for staphylococcal protein a resulting in the activation of NF Kappa b, ap-1, and downstream gene transcription. Exp. Dermatol. 2011, 20, 48-52. [CrossRef] [PubMed]
95. Grigg, J.C.; Ukpabi, G.; Gaudin, C.F.; Murphy, M.E. Structural biology of heme binding in the Staphylococcus aureus isd system. J. Inorganic Biochem. 2010, 104, 341-348. [CrossRef] [PubMed]
96. Clarke, S.R.; Brummell, K.J.; Horsburgh, M.J.; McDowell, P.W.; Mohamad, S.A.; Stapleton, M.R.; Acevedo, J.; Read, R.C.; Day, N.P.; Peacock, S.J.; et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 2006, 193, 1098-1108. [CrossRef] [PubMed]
97. Clarke, S.R.; Andre, G.; Walsh, E.J.; Dufrene, Y.F.; Foster, T.J.; Foster, S.J. Iron-regulated surface determinant protein a mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect. Immunity 2009, 77, 2408-2416. [CrossRef] [PubMed]
98. Clarke, S.R.; Mohamed, R.; Bian, L.; Routh, A.F.; Kokai-Kun, J.F.; Mond, J.J.; Tarkowski, A.; Foster, S.J. The Staphylococcus aureus surface protein isda mediates resistance to innate defenses of human skin. Cell Host Microbe 2007, 1, 199-212. [CrossRef] [PubMed]
99. Clarke, S.R.; Foster, S.J. Isda protects Staphylococcus aureus against the bactericidal protease activity of apolactoferrin. Infect. Immunity 2008, 76, 1518-1526. [CrossRef] [PubMed]
100. Kuklin, N.A.; Clark, D.J.; Secore, S.; Cook, J.; Cope, L.D.; McNeely, T.; Noble, L.; Brown, M.J.; Zorman, J.K.; Wang, X.M.; et al. A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immunity 2006, 74, 2215-2223. [CrossRef] [PubMed]
101. Ebert, T.; Smith, S.; Pancari, G.; Clark, D.; Hampton, R.; Secore, S.; Towne, V.; Fan, H.; Wang, X.M.; Wu, X.; et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (isdb) with functional activity in vitro and in vivo. Hum. Antib. 2010, 19, 113-128.
102. Brown, M.; Kowalski, R.; Zorman, J.; Wang, X.M.; Towne, V.; Zhao, Q.; Secore, S.; Finnefrock, A.C.; Ebert, T.; Pancari, G.; et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin. Vaccine Immunol. 2009, 16, 1095-1104. [CrossRef] [PubMed]
103. Kim, H.K.; DeDent, A.; Cheng, A.G.; McAdow, M.; Bagnoli, F.; Missiakas, D.M.; Schneewind, O. Isda and isdb antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010, 28, 6382-6392. [CrossRef] [PubMed]
104. Stranger-Jones, Y.K.; Bae, T.; Schneewind, O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2006, 103, 16942-16947. [CrossRef] [PubMed]
105. Narita, K.; Hu, D.L.; Mori, F.; Wakabayashi, K.; Iwakura, Y.; Nakane, A. Role of interleukin-17a in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor a. Infect. Immunity 2010, 78, 4234-4242. [CrossRef] [PubMed]
106. Nissen, M.; Marshall, H.; Richmond, P.; Shakib, S.; Jiang, Q.; Cooper, D.; Rill, D.; Baber, J.; Eiden, J.; Gruber, W.; et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (sa3ag) in healthy adults. Vaccine 2015, 33, 1846-1854. [CrossRef] [PubMed]
107. Proctor, R.A. Recent developments for Staphylococcus aureus vaccines: Clinical and basic science challenges. Eur. Cells Mater. 2015, 30, 315-326.
108. Schmidt, C.S.; White, C.J.; Ibrahim, A.S.; Filler, S.G.; Fu, Y.; Yeaman, M.R.; Edwards, J.E.; Hennessey, J.P.. Ndv-3, a recombinant alum-adjuvanted vaccine for candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012, 30, 7594-7600. [CrossRef] [PubMed]